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Dendritic cells (DCs) are critical for adaptive immunity and tolerance.Most DCs are strategically positioned as
immune sentinels poised to respond to invading pathogens in tissues throughout the body. Differentiated
DCs and their precursors also circulate in blood and can get rapidly recruited to sites of challenge. Within
peripheral tissues, DCs collect antigenic material and then traffic to secondary lymphoid organs, where
they communicate with lymphocytes to orchestrate adaptive immune responses. Hence, the migration
and accurate positioning of DCs is indispensable for immune surveillance. Here, we review the molecular
traffic signals that govern the migration of DCs throughout their life cycle.Introduction
Dendritic cells (DCs) are specialized antigen-presenting cells that
play adual role in inducing adaptive immune responses to foreign
antigens (Ags) and in maintaining T cell tolerance to self (Stein-
man and Banchereau, 2007). DCs consist of several distinct
subsets distinguishable by surface and intracellular phenotypic
markers, immunological function, and anatomic distribution (Ta-
ble 1). Inmice, all DCs express (in varying amounts) theCD11c in-
tegrin and MHC class-II (MHC-II) molecules, and they are further
phenotypically distinguished by their differential expression of
CD8a, CD4, CD11b, Langerin, and PDCA-1, as well as a growing
list of other markers (Shortman and Naik, 2007). These markers
have been used in various combinations to define several sub-
populations; some of these are highly restricted to specific or-
gans, whereas others occur at characteristic frequencies among
a mixture of DC subsets, especially in secondary lymphoid or-
gans (SLOs). Arguably the clearest phenotypic and functional
distinction can be made between the bulk of CD11chi MHC-II+
DCs (conventional DCs, or cDCs) and the type I interferon-pro-
ducing plasmacytoid DCs (pDCs), which are CD11clo MHC-II+/lo
and express unique differentiation markers in both mice and
humans. Irrespective of their phenotypic idiosyncracies or immu-
nological role, DCsexert their activity in discrete locations remote
from their place of origin, which implies that DCs possess
advanced migratory skills to navigate through the body.
All DCs ultimately derive fromhematopoietic stemandprogen-
itor cells (HSPCs) in the bone marrow (BM). HSPCs give rise to
several distinct progenitors that can differentiate into one or
more DC subsets (Fogg et al., 2006; Naik et al., 2007; Onai
et al., 2007). Facultative DC progenitors are not restricted to the
BM (although some fully differentiated DCs are generated there)
but can be found in multiple locations, including the thymus,
blood, lymph, and most visceral organs (Liu et al., 2007; Mass-
berg et al., 2007; Onai et al., 2007). These progenitors can differ-
entiate into DCs upon challenge in peripheral tissues (Massberg
et al., 2007). Substantial numbers of DCs are also physiologically
generated in the thymus (Wu and Shortman, 2005).Fully differentiated DCs are found in healthy tissues as immu-
nologically immature cells, i.e., they are equipped with highly
active endocytic machinery for the sampling of foreign Ags but
have not acquired the capacity for full-fledged priming of naive
T cells (Banchereau et al., 2000). Some tissues are notably en-
riched for DCs; such tissues include the skin and mucosal sur-
faces, the most common sites of entry for microbial pathogens,
and the SLOs, where adaptive immune responses to such path-
ogens are initiated. Indeed, a central function of DCs in nonlym-
phoid tissues is the transport and presentation of antigenic cargo
into and within SLOs. This is owed to the DCs’ ability to enter
small lymph vessels in peripheral tissues and migrate to local
draining lymphnodes (LNs). Somewhere en route to the LN, these
Ag-bearing DCsmature, i.e., they assume an immunostimulatory
phenotype concurrent with increased expression of MHC
complexes and upregulation of the costimulatory molecules
and cytokines needed for efficient T cell priming. A small fraction
of DCs that enter lymphatics are not retained in LNs; rather,
they travel along the lymphatic tree to the venous circulation.
These blood-borne DCs can deliver their antigenic cargo to the
spleen (Mullins et al., 2003) and to primary lymphoid tissues,
i.e., the BM (Cavanagh et al., 2005) and thymus (Bonasio et al.,
2006).
Given this complex life cycle, the ability of DCs and their pro-
genitors to migrate throughout the body is a critical aspect of
their immunological function. The term ‘‘migration,’’ as dis-
cussed here, encompasses several discrete events that occur
in different environments under different biophysical conditions
and invoke numerous context-specific cellular and molecular
mechanisms (Figure 1). Specifically, DCmigration entails the fol-
lowing: (1) the ability of newly formed DCs or their progenitors to
exit their place of birth (i.e., the BM and possibly also the thymus)
and enter the blood; (2) the recruitment of the circulating cells
into target tissues; (3) the extravascular lodging and interstitial
motility needed to sample Ags; (4) the capacity to access lymph
vessels to travel either to LNs or back to the blood; and (5) the
ability to interact with migrating lymphocytes and other immuneImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 325
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References included in this table are as follows: (Wright et al., 2002;Massberg et al., 2007; Fogg et al., 2006; Onai et al., 2007;
Naik et al., 2007; Geissmann et al., 2003; Ley et al., 2007; Bursch et al., 2007; Stutte et al., 2008; Poulin et al., 2007; Ginhoux
et al., 2007; Stutte et al., 2008; Bonasio et al., 2006; Cavanagh et al., 2005; Jung et al., 2000; Bonasio et al., 2006; Vremec
et al., 2000; Cella et al., 1999; Diacovo et al., 2005; Penna et al., 2001; Vermi et al., 2005; Zabel et al., 2005; Hammad and
Lambrecht, 2007; Iwasaki, 2007).cells in a manner that allows the exchange of critical information
regarding the nature and context of presented Ags. Here, we will
discuss our current understanding of each of these migration
events and provide a programmatic overview of the life cycle
of DCs while paying particular attention to the mechanisms
and consequences of DC migration. We will primarily focus on326 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.data derived from mouse models and, where appropriate, high-
light parallels and differences between mice and humans.
Methods of Studying DC Migration
Many DCs begin their journey with their release from the BM into
the blood and subsequent traffic into peripheral lymphoid and
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proceed into LNs through afferent lymphatics and, in some in-
stances, return back to the blood via the thoracic duct (TD).
Throughout this voyage, migrating DCs must apply specialized
skills to reach their target destination. Such skills include the
capacity to traverse vessel walls and other anatomic barriers;
recognize and adhere to specific microvascular endothelial cells
in the presence of shear stress in the bloodstream; sense and fol-
low soluble and surface-bound chemoattractant cues through
the interstitium; and scan and interact productively with a vast
number of lymphocytes in SLOs. Although no single method in
the immunologist’s toolbox sufficiently covers all the diverse
steps that constitute a DC’s longwinded voyage, the combined
application of the techniques discussed below has been instru-
mental in fleshing out an ever more detailed picture of how
DC migration impacts physiological and pathological immune
responses.
A number of techniques have been particularly useful in study-
ing DC trafficking from blood into peripheral tissues or SLOs.
These include intravital videomicroscopy (IVM) (Cavanagh
et al., 2005; Robert et al., 1999) and flow-cytometric or histol-
ogy-based DC homing assays (Ingulli et al., 1997), which provide
useful information at the single-cell and population levels, re-
spectively. A detailed analysis of DC interactions with endothelial
ligands under precisely controlled biophysical conditions is also
afforded by the use of flow-chamber devices (Geijtenbeek et al.,
2000). In vitro chemotaxis assays have provided profound in-
sights into DC traffic signals involved in transvascular diapedesis
and interstitial navigation (Lin et al., 1998).
Trafficking of DCs from tissues to SLOs via the lymph has been
exhaustively studied, in particular by classic assays that mobilize
DCs from peripheral tissues with fluorescent tracers and subse-
quent enumeration of the emigration and immigration of fluores-
cent DCs from the periphery and into the draining LN (Bonasio
and von Andrian, 2006). This approach relies on the assumption
that the number and phenotype of fluorescent DCs recovered
from a LN are indicative of their migration and not due to acqui-
sition of fluorescent tracer by LN-resident cells. A more recent
approach involves genetic manipulations that permanently or
conditionally label DCs through fluorescent proteins driven, for
example, by promoters for langerin (Kissenpfennig et al., 2005)
or CD11c (Lindquist et al., 2004). This offers the advantage
that unperturbed endogenous DCs can be studied in situ but
has the potential drawback that reporter expression levels may
change during maturation or differentiation. The development
of a photoconvertible fluorescent protein, Kaede, which upon
exposure to UV light shifts its excitation and emission spectrum,
has emerged as another useful system for monitoring the cellular
trafficking patterns, including those of DCs, in transgenic mice
(Tomura et al., 2008). Purified or in vitro differentiated DCs
have also been genetically or chemically labeled and injected
into tissues so that their trafficking to and function within draining
LNs can be studied (Ingulli et al., 1997; Smith and Fazekas de St
Groth, 1999). This allows formore quantitative and time-resolved
analyses of the molecular mechanisms, kinetics, and immuno-
logical sequelae of DC migration. However, these approaches
warrant mention of several caveats, including the large, nonphy-
siological numbers of DCs that must be transferred, the need for
ex vivo manipulation, and the fact that transferred DCs are notnative to the tissue being studied. In this regard, parabiotic or
competitive BM chimeric mouse models offer advantages for
studying physiological recruitment and turnover of DCs and, in
conjunction with adoptive-transfer strategies, have been useful
in addressing themigration and differentiation of rare DC precur-
sors (Liu et al., 2007; Massberg et al., 2007; Naik et al., 2007;
Onai et al., 2007).
Technological advances in IVM and multi-photon (MP) imag-
ing have recently enabled researchers to directly visualize DC
migration and DC interactions in their native environment
(Bousso and Robey, 2003; Mempel et al., 2004; Miller et al.,
2004a). Conventional IVM uses brightfield transillumination or
epifluorescence microscopy that permits two-dimensional
imaging of intravascular adhesion events in surgically exposed
tissues in real time (Halin et al., 2005). This approach has helped
to pinpoint the precise role of trafficking molecules during DC-
endothelium interactions as part of the intravascular multistep
adhesion cascade (discussed below). MP-IVM uses infrared-
pulsed laser excitation to generate high-resolution optical
sections of living tissue containing fluorescently labeled cells,
such as DCs, migrating and engaging in various cell-cell interac-
tions (Cahalan et al., 2002). Additional novel imaging modalities,
such as bioluminescence imaging, magnetic resonance imaging,
and positron emission tomography, have recently been intro-
duced, and theseprovidenon-invasive trackingof leukocyte pop-
ulations, includingDCs, throughout theentire body, although they
do sowith considerably less spatial and/or temporal resolution for
visualizing single-cell dynamics (Baumjohann and Lutz, 2006).
Traffic Molecules in DC Migration
Circulating DCs and their precursors exit the blood in response
to tissue-specific recruitment signals that are displayed on the
vascular wall. These include signals that emanate from sites of
inflammation (such as the pro-inflammatory chemokines (che-
motactic cytokines)) or from normal tissues that recruit DC pre-
cursors during the initial seeding and subsequent physiological
turnover of tissue-resident DCs (Elbe et al., 1989). Circulating
leukocytes can only follow these recruitment signals by engaging
adhesion molecules, which allow them to withstand the shear
stress exerted by microvascular blood flow and to commence
transvascular movement into the target tissue. DCs express
specific adhesion molecules andmaturation-dependent chemo-
attractant receptors that allow them to respond to a variety of
ligands (Sozzani et al., 1997; Sozzani et al., 1995), which control
their trafficking. For example, to access nonlymphoid peripheral
tissues and navigate within them, immature DCs (and some of
their precursors, particularly monocytes) utilize specific chemo-
kine receptor-ligand pathways, such as CCR2-CCL2 (Geiss-
mann et al., 2003; Merad et al., 2002), CCR5-CCL5 (Stumbles
et al., 2001; Yamagami et al., 2005), and CCR6-CCL20 (Merad
et al., 2004). When DCs becomemature, they downregulate their
responsiveness to these inflammatory chemokine pathways and
traffic to the draining LNs by upregulating CCR7, which re-
sponds to two ligands, CCL19 and CCL21 (Dieu et al., 1998;
Sallusto et al., 1998; Sozzani et al., 1998). These chemokines
are expressed by peripheral lymphatic endothelial cells as well
as LN stroma cells and guide DCs to downstream LNs (Martin-
Fontecha et al., 2003; Saeki et al., 1999; Vassileva et al., 1999).Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 327
Immunity
ReviewDCs and their precursors are recruited from blood into tissues
(except the spleen) after a cascade of sequential molecular and
cellular interactions, analogous to what has been shown for the
extravasation of other circulating leukocytes. According to this
paradigm, leukocyte extravasation occurs in a series of distinct
steps including tethering, rolling, activation by a chemoattrac-
tant, firm adhesion, and diapedesis (von Andrian and Mackay,
2000). On most leukocytes, including circulating DCs, tethering
and rolling are primarily mediated by one or more of the three
members of the selectin family and occasionally by a4 integrins.
Two selectins, P- and E-selectin, are expressed on activated
endothelium, whereas L-selectin is found on leukocytes.
Selectins bind sialyl-Lewis X-like carbohydrates presented by
sialomucins, such as P-selectin glycoprotein ligand 1 (PSGL-1)
(Vestweber and Blanks, 1999).
Rolling cells must next encounter a chemoattractant stimulus,
often (but not always) in the form of a chemokine presented on
venular endothelial cells (Rot and von Andrian, 2004). Most che-
moattractants signal through pertussis toxin (PTX)-sensitive G
protein-coupled receptors (GPCRs), causing clustering and con-
formational activation of integrins. Activated integrins, in partic-
ular LFA-1 (aLb2), VLA-4 (a4b1), Mac-1 (aMb2), and a4b7, medi-
ate firm arrest of the rolling cells by binding to members of the
immunoglobulin superfamily (IgSF), including ICAM-1 (ligand
for LFA-1 and Mac-1), ICAM-2 (ligand for LFA-1), VCAM-1 (li-
gand for VLA-4 and weakly for a4b7) and MAdCAM-1 (ligand
for a4b7) (Springer, 1994).
Upon firm arrest, leukocytes respond to localized chemoat-
tractant and/or adhesion molecule gradients, which provide
guidance cues for diapedesis and directed leukocyte migration.
The essential molecular determinants involved in tethering,
rolling, firm adhesion and diapedesis are expressed by both cir-
culating DCs and DC precursors, such as monocytes (Imhof
and Aurrand-Lions, 2004) and HSPCs (Laird et al., 2008). Indeed,
Figure 1. Programmatic Outline of DC and DC-Precursor
Trafficking Routes
DCs develop from precursors that originate from primary lymphoid tissues
(PLT) such as the BM and the thymus. Precursors and committed DCs en-
ter the circulation and seed peripheral tissues and SLOs (see also Figure 2
for an overview of the hematogenous route). From peripheral tissues, they
can access afferent lymph upon receiving a mobilization signal and travel
to the draining LN (see also Figure 3 for migration to the draining LN and
Figure 4 for migration within the LN). Leukocytes leave LNs via the efferent
lymph and are collected in the TD, which eventually guides DCs and their
precursors back into the circulation. For individual migratory routes for
specific DCs and their precursors, refer to Table 1.
IVM experiments have determined that both cDCs and pDCs
tether and roll efficiently along venular endothelium in an E-
and P-selectin-dependent fashion and, like other inflamma-
tory cells, canbe recruited fromtheblood to sitesof inflamma-
tion (Diacovo et al., 2005; Robert et al., 1999).
The combinatorial use of selectins, chemoattractant re-
ceptors, integrins, and their respective ligands provides for
a great deal of diversity and selectivity in regulating leukocyte
migration to distinct tissues (Springer, 1994). Individual leu-
kocyte subsets, including DCs, express only a small selec-
tion of the broad palette of traffic molecules and, therefore,
can only successfully participate in one or a few specific
multi-step cascades. Conversely, many specializedmicrovascu-
lar endothelial cells present a highly tissue-specific assortment
of adhesion molecules and chemoattractants and thus provide
a unique tissue- and situation-specific molecular ‘‘area code.’’
In the subsequent section, we highlight specific examples of
how multistep adhesion cascades control the movement of in-
travascular DCs and their precursors into different target organs.
DC Migration from Blood to Tissues
Blood contains both DC precursors and differentiated DC sub-
sets, including pDCs and cDCs, which are a mixture of newly
generated cells from the BM and experienced DCs that have
re-entered the circulation from peripheral tissues (Bonasio and
von Andrian, 2006). There are also pluripotent HSPCs, which re-
circulate continuously between the blood, peripheral organs,
and draining lymphatics and can give rise to DCs upon TLR liga-
tion (Massberg et al., 2007). Blood contains also lineage-com-
mitted BM-derived DC precursors that can differentiate into
any DC subset found in SLOs (Fogg et al., 2006; Naik et al.,
2007; Onai et al., 2007). An additional source of DCs is circulating
monocytes (Gordon and Taylor, 2005). In mice and humans, two
monocyte subsets that are distinguished by the differential
expression of Ly-6C (in mice) and three traffic molecules,
CX3CR1, CCR2, and L-selectin, have been identified (Geiss-
mann et al., 2003; Palframan et al., 2001). Ly-6Chi CX3CR1
lo
CCR2hi (‘‘inflammatory’’) monocytes are preferentially recruited
to distressed tissues in a CCR2–CCL2 (MCP-1)-dependent man-
ner. They can give rise to a variety of cDCs under both inflamma-
tory and steady-state conditions. The second subset, Ly-6C
CX3CR1
hi CCR2lo/ (‘‘resident’’) monocytes, interacts with
fractalkine (CX3CL1), a transmembrane chemokine on resting
endothelium. These cells patrol the lumenal surface of microves-
sels, enter tissues upon inflammation, and differentiate into
macrophages (Auffray et al., 2007; Geissmann et al., 2003).328 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.
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This schematic outline illustrates various routes that DCs can take to and from the blood into various lymphoid and nonlymphoid tissues. DC precursors are
released from the BM and enter the blood pool, which consists of: cDCs (or cDCs), pDCs, and DC precursors (encompassing monocytes, HSPCs, and other
committed DC precursors). Potential destinations of blood-borne DCs as well as the major trafficking molecules implicated in their migration are highlighted.
Destinations include (from left to right) the skin, LN, thymus, and spleen. Also shown is their re-entry into the BM.An abrupt increase in circulating DC numbers occurs when
DCs are injected intravenously. Although nonphysiological,
such events are clinically relevant because antigen-pulsed autol-
ogous DCs have been given to patients by various routes as anti-
cancer vaccines (Steinman and Banchereau, 2007). This clinical
context highlights the importance of understanding the target
organs of circulating DCs and the molecular mechanisms that
govern their migration to those sites. Irrespective of their origin
and differentiation state, circulating DCs and their precursors
gain access to lymphoid and nonlymphoid tissues through
multi-step adhesion cascades. The molecules involved in dis-
crete adhesion steps vary depending on the DC subset and
the target tissue, thus providing specificity and selectivity in
recruitment (Figure 2).
DC Traffic to Nonlymphoid Tissues
The recruitment mechanisms that guide fully committed imma-
ture or mature DCs from blood into nonlymphoid tissues are
only partly characterized. Our current knowledge ismainly based
on adoptive transfers of labeled DCs by intravenous (i.v.) injec-
tion. Amajor fraction of injectedmature and immature DCs accu-
mulates in the liver and lungs in mice and humans (Cavanagh
et al., 2005; de Vries et al., 2005; Morse et al., 1999). Althoughthe underlyingmechanisms governing this distribution are poorly
understood, the retention of DCs in the lungs is probably due, at
least in part, to mechanical trapping in pulmonary capillaries,
rather than active adhesion (Cavanagh et al., 2005).
IVM experiments have shown that cDCs can efficiently tether
and roll in normal murine skin venules, which constitutively
express E- and P-selectin (Robert et al., 1999). Because sLeX-
decorated PSGL-1, the principal ligand for the vascular selectins,
is highly expressed not only on DCs (Robert et al., 1999) but also
on monocytes and HSCs (Laird et al., 2008; Lim et al., 1998), it is
likely that all DCs and DC precursors can engage in rolling inter-
actions in microvascular beds that express P- and/or E-selectin
either constitutively (e.g., in skin, BM, and thymus) or in response
to inflammation. Interestingly, DC extravasation into inflamed
skin depends on selectins but not on PSGL-1, suggesting a
contribution by other selectin ligands on DCs (Pendl et al., 2002).
Although selectins are clearly important, they mediate only the
first step in the multistep adhesion cascade and do not by them-
selves support DC arrest or accumulation in normal skin. Addi-
tional signals are required to trigger integrin activation, arrest,
and subsequent diapedesis (Pendl et al., 2002; Robert et al.,
1999). However, little is known about the inflammation-induced
or constitutive chemoattractants that trigger these steps. DirectImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 329
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normal tissues are particularly challenging because these are
very rare events that may only become prominent after long-
term adoptive transfers or in parabiosis settings. Some informa-
tion may be gleaned from in vitro experiments. For example, a
recent study found a role for the IgSF molecule ICAM-2 in the
transmigration of immature DCs across endothelial monolayers
(Wethmar et al., 2006).
Lineage-committed DC precursors (other than monocytes)
have not been examined so far for their capacity to home to
normal tissues other than SLOs. Reconstitution experiments in
irradiated mice with wild-type and mutant BM have shown that
circulating LC precursors repopulate severely inflamed skin in
a CCR2- and CCR6-dependent manner, but these pathways
are apparently not operational in normal skin (Merad et al.,
2004; Merad et al., 2002). Accordingly, the CCR2 ligands, CCL2
and CCL7, and the CCR6 ligand, CCL20, are poorly expressed
in resting tissues but are markedly increased in inflamed skin
(Dieu-Nosjean et al., 2000;Merad et al., 2004;Merad et al., 2002).
The so-called inflammatory CX3CR1
lo CCR2+ Ly6Chi mono-
cytes can enter diverse inflamed tissues, including the skin,
lung, and intestinal lamina propria, where they give rise to various
DC subsets (Ginhoux et al., 2006; Landsman et al., 2007; Varol
et al., 2007). The CX3CR1
hi CCR2 Ly6Clo monocytes can also
give rise to DCs (or at least CD11c+ cells) in the lung (Landsman
et al., 2007) and atherosclerotic plaques (Tacke et al., 2007).
However, the role of specific traffic molecules in each case is
largely unclear. Arguably the best evidence exists for CCR2 be-
cause Ly6Chi monocytes fail to accumulate at sites of inflamma-
tion in Ccr2/ mice (Merad et al., 2002). However, it must be
noted that CCR2 controls the inflammation-induced release of
monocytes from the BM (Serbina and Pamer, 2006). Thus, the
observed migration defect could reflect either poor monocyte
mobilization or defective peripheral recruitment, or both.
Circulating pDCs can also access inflamed tissues, but their
homing properties are thought to differ substantially from those
of cDCs. Compared to the latter, human pDCs exhibit only
a weak capacity in vitro to migrate toward pro-inflammatory
chemokines (e.g., CCL2, CCL5, and CCL20) despite expressing
a similar chemokine receptor profile (e.g., CCR2, CCR5, CXCR3,
CXCR4, and CCR7) (Penna et al., 2001). On the other hand,
pDCs migrate effectively toward CCL19 and CCL21, two ho-
meostatic chemokines that act on CCR7 and are constitutively
expressed in SLOs (Penna et al., 2001). Indeed, substantial num-
bers of pDCs are found in SLOs, but they are relatively infrequent
in most nonlymphoid tissues (for a detailed discussion of pDC
distribution, the reader may refer to the article by Villadangos
and Young in this issue (2008)). In humans, pDCs are enriched
in certain inflamed nonlymphoid tissues, such as lupus erythe-
matosus lesions (Farkas et al., 2001), psoriatic skin (Nestle
et al., 2005), and the nasal mucosa of allergic rhinitis patients
(Jahnsen et al., 2000), but it has not been determined whether
their presence at those sites reflects recruitment of differentiated
circulating pDCs or local differentiation from progenitors. Direct
recruitment of blood-borne pDCs has been documented in nor-
mal and inflamed small intestine in mice; pDCs require CCR9 to
access the intestinal wall, which physiologically generates
CCL25, the ligand for CCR9 (Wendland et al., 2007). Another
chemoattractant for circulating pDCs is chemerin (Vermi et al.,330 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.2005; Zabel et al., 2005). This nonchemokine molecule is gener-
ated by serine proteases that are activated during coagulation,
fibrinolysis, and inflammation. Chemerin is absent from normal
skin but is markedly upregulated during cutaneous inflammation
and recruits pDCs via the serpentine chemokine-like receptor 1
(CMKLR1 or ChemR23).
DC Traffic to Primary Lymphoid Tissue
Some fully committed DCs recirculate from peripheral tissues via
the draining lymphatics and blood into primary lymphoid tissues.
Through this tortuous route, DCs can deliver Ag from all over the
body to both the BM and the thymus. However, immunological
consequences in each tissue are markedly different. The BM
shares a number of features with bona fide SLOs and serves
as a major reservoir for memory T cells (Di Rosa and Pabst,
2005). Ag-laden circulating DCs that home to the BM evoke a
vigorous memory response that leads to rapid proliferation and
peripheralization of responsive T cells (Cavanagh et al., 2005).
Immature and mature DCs enter the BM equally well by employ-
ing a multistep adhesion cascade. IVM in mouse skull BM has
shown that rolling is mediated by interactions of PSGL-1 with
P- and E-selectin in BM venules and sinusoids, whereas VLA-
4–VCAM-1 is required for sticking. Although DCs express b2 in-
tegrins, homing to the BM is independent of thesemolecules. DC
homing to BM is also not affected by PTX treatment, suggesting
that DCs might activate VLA-4 by using an as-yet-unidentified
chemoattractant receptor(s) that does not signal through the
conventional Gai pathway (Cavanagh et al., 2005).
The thymus harbors two distinct populations of DCs; one is
derived from intrathymic early lymphoid progenitors, whereas
the second population originates from the periphery (Donskoy
and Goldschneider, 2003; Kamath et al., 2000). Ag presentation
by either DC subset in the thymus shapes the developing T cell
repertoire and results in central tolerance, rather than immunity
(Steinman et al., 2003). Monocytes or DC precursors have not
been observed to home to the thymus (Geissmann et al., 2003;
Naik et al., 2007). By contrast, parabiosis and adoptive transfer
experiments have established that small numbers of fully differ-
entiated DCs constantly enter the thymus from the blood (Bona-
sio et al., 2006; Donskoy and Goldschneider, 2003). This ability
to home to the thymus is shared by all immature DC subsets.
Inflammation-induced maturation selectively blocks the capac-
ity of DCs to home to the thymus but does not compromise
DC trafficking to other organs (Bonasio et al., 2006). This sug-
gests amechanism for safeguarding against inadvertent deletion
of T cells that recognize pathogen-associated Ags, which are
much more likely to be presented by mature than immature
DCs. The differential capacity of immature DCs to access the
thymus is probably regulated by an organ-specific multistep
adhesion cascade, whereby rolling and sticking are mediated
by PSGL-1–P-selectin and VLA-4–VCAM-1, respectively. Unlike
in the BM, DC entry into the thymus is PTX sensitive, but the
specific Gai-coupled chemoattractant receptor(s) remain(s) to
be identified (Bonasio et al., 2006).
DC Traffic from Blood to SLOs
Parabiosis studies and adoptive transfer experiments indicate
that committed DC precursors have a very short half-life in the
circulation (Liu et al., 2007). In these experiments, the degree
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degree of chimerism among fully differentiated DCs in SLOs.
This suggests that SLO-resident DCs are constantly replen-
ished by circulating DC precursors, although the mechanisms
of precursor recruitment are unclear.
The rules that govern the entry of DCs and their precursors into
LNs are complex. Intravenously administered, fully differentiated
cDCs fail to egress across high endothelial venules (HEVs) into
normal LNs and Peyer’s patches (PPs) (Cavanagh et al., 2005;
Robert et al., 1999). This is consistent with the fact that the
multi-step adhesion cascades that recruit leukocytes to both
SLOs depends on L-selectin (and in PP on a4b7 integrin) and
CCR7 (von Andrian and Mempel, 2003). In contrast to cDCs,
pDCs can enter reactive LNs from the circulation via HEVs (Cella
et al., 1999; Diacovo et al., 2005). IVM experiments have shown
that BM-derived pDCs roll in activated HEVs by employing
L-selectin–peripheral node addressin (PNAd) and PSGL-1–E-se-
lectin interactions. Moreover, firm arrest occurred via b1 and b2
integrins and CCR5, but not CXCR3 (Diacovo et al., 2005). How-
ever, BM-derived pDCs express elevated amounts of L-selectin,
PSGL-1, LFA-1, and VLA-4 compared to their endogenous
counterparts (Diacovo et al., 2005). Indeed, ex vivo isolated,
adoptively transferred pDC precursors reportedly do not employ
L-selectin to enter inflamed LNs (Yoneyama et al., 2004).
UncommittedDCprecursors, particularlymonocytes, can also
take a hematogenous route to access LNs that drain inflamed
tissues. This pathway involves a remote-control mechanism,
whereby chemokines are produced at a peripheral site of inflam-
mation, enter afferent lymphconduits and are then transported to
the luminal surface of HEVs (Palframan et al., 2001). This mecha-
nism has been documented for the inflammatory chemokine
CCL2, whose de novo presence in HEVs combined with other
endothelial traffic molecules, such as PNAd and E-selectin,
enables the recruitment of CCR2+ monocytes (Palframan et al.,
2001). This ‘‘inflammatory’’ monocyte population is a known
source of DCs (Geissmann et al., 2003). Some monocytes may
also be recruited to LN HEVs through another inflammatory
chemokine, CXCL9, a ligand for CXCR3, although this receptor
is only found on a small subset of monocytes (Janatpour et al.,
2001).
Like most blood-borne cells, circulating DCs and their various
progenitors can be retained in the spleen (Bonasio et al., 2006;
Cavanagh et al., 2005; Liu et al., 2007). However, it is unclear to
what extent newly homed cells contribute to the various
resident DC subsets and their precursors in the spleen. Adop-
tive-transfer experiments have shown that DCs enter the spleen
from the circulation in the marginal zone (MZ) sinus at the border
between white and red pulp (Austyn et al., 1988). The traffic sig-
nals that recruit (or release) DCs to (or from) the spleen are largely
unknown. One molecule that has been implicated in this process
is the IgSF member CD47, a ligand for SIRP-a (Van et al., 2006).
CD47-deficient mice have reduced numbers of DCs in the MZ,
but this finding is complicated by the fact thatCD47-deficient cells
are rapidly cleared by splenic macrophages (Blazar et al., 2001).
DC Entry into Afferent Lymphatics
and Migration to Draining LNs
A small but continuous stream of DCs leave nonlymphoid
tissues, access the lymphatics, and migrate to downstreamLNs at steady state (Brand et al., 1992). This physiological trickle
can turn into a veritable flood when tissues are exposed to in-
flammation. Irrespective of the inflammatory state, lymph ves-
sels provide a crucial information conduit by relaying DC-bound
and -unbound antigenic material from the periphery to the local
LNs. DC migration into and along this conduit occurs through
a series of steps, including (1)mobilization, (2) detachment, (3) in-
terstitial migration, (4) entry into the afferent lymphatics, and (5)
transit via lymph (Figure 3). Though DCs in all tissues may follow
similar migratory cues, our understanding of this process arises
predominantly from experimental data obtained in the skin.
Mobilization Signals
That DCs migrate from peripheral tissues to LNs was first noted
in the 1970s when changes in LC density and distribution be-
tween epidermal and dermal skin layers and lymph vessels
were observed upon contact sensitization (Silberberg-Sinakin
et al., 1976). Today, it is firmly established that DCs aremobilized
in response to a large variety of proinflammatory stimuli that can
be chemical (e.g., contact sensitizers and irritants), physical
(e.g., UV radiation or trauma), or biological (e.g., microbial or tis-
sue necrosis). The initial exposure to such inflammatory stimuli
first induces a brief interval of immobility and enhanced endo-
cytic Ag uptake followed within hours by a period of maturation
whereby DCs regain their motility, re-arrange their repertoire of
chemokine receptors, upregulate their Ag presentation machin-
ery, and eventually migrate to LNs (Granucci et al., 1999). De-
spite their diverse nature, most DC mobilization signals appear
to exert their activity through a pair of intermediate messengers,
IL-1b and TNF-a. This was first demonstrated for contact sensi-
tizers, which rapidly induce a marked increase in intra-epidermal
mRNA levels for these two cytokines (Enk and Katz, 1992). The
importance of IL-1b and TNF-a in contact hypersensitivity and
DC migration was subsequently validated by experiments in-
volving cytokine neutralization (Cumberbatch and Kimber,
1995; Enk et al., 1993) and in mice deficient in the TNF-a type
II receptors (Wang et al., 1997), the IL-1 type I receptor (Cumber-
batch et al., 1999), and caspase-1, a protease required for re-
lease of active IL-1b (Antonopoulos et al., 2001). IL-1b or
TNF-a is not only required but also sufficient for DC mobilization
given that subcutaneous administration of either cytokine alone
promotes rapid DC migration to LNs in the absence of other
stimuli (Cumberbatch et al., 1997). The mechanism(s) by which
these cytokines prompt DC migration probably include altered
expression in adhesion molecules and chemokine receptors on
DCs along with a differential responsiveness to the relevant
chemotactic ligands in the local microenvironment, which pave
the way for DCs to traffic to downstream LNs.
Small numbers of DCs also traffic to LNs in the absence of
inflammatory stimuli, as evidenced by the presence of DCs in
afferent lymph (Brand et al., 1992; Bujdoso et al., 1989). Addi-
tional evidence for steady-state DC migration stems from recent
experiments in Kaede transgenic mice; these experiments pro-
vided quantitative estimates of the number of DCs that reach
a cutaneous LN from the skin (5% of total LN DCs per day) (To-
mura et al., 2008). The signals that prompt this ‘‘spontaneous’’
DC migration have proven difficult to pinpoint, in part, because
most experimental migration assays induce some form of inflam-
mation. Despite this, evidence supports a role for CCR7 (ForsterImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 331
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This schematic illustrates a proposed model for the interstitial migration for skin DCs from the cutaneous microenvironment to the afferent lymphatics en route to
the LN. Themigratory cascade is divided into five discrete steps (clockwise from top left), startingwith recognition of amobilizing signal (inset 1), detachment from
structural tissue elements (inset 2), trafficking through interstitial space (inset 3), transit through the afferent lymphatic endothelium (inset 4), and transit through
the afferent lymph vessels (inset 5). Major chemokine-chemokine receptor (CKRs) pathways and other trafficking molecules controlling DC migration are
highlighted.et al., 1999) and S1P receptors (Maeda et al., 2007), although the
precise step(s) where these pathways are required is unclear.
Murine immature BM-derived DCs express S1P receptors
S1P2-4, yet unlike their mature counterparts, they are unrespon-
sive to S1P (Czeloth et al., 2005). By contrast, human immature,
but not mature, blood-derived DCs are responsive to S1P (Idzko
et al., 2002). CCR7 is required for DC entry into dermal afferent
lymphatics. Consequently, fewer putative migratory DCs are
found in LNs of CCR7-deficient mice than in wild-type controls
when both are kept under specific pathogen- or germ-free con-
ditions (Ohl et al., 2004). However, immature DCs are not thought
to express CCR7, nor do they chemotax toward its ligands
(Sallusto et al., 1998). Indeed, CCR7 is generally only induced
when DCs encounter proinflammatory maturation signals (Yana-
gihara et al., 1998). A potential solution to this conundrum may
be that some steady-state DCs upregulate CCR7 but mature
only partially.332 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.In support of a dissociated induction ofCCR7are results show-
ing that the activation of the surface Ig-like receptor TREM-2 (trig-
gering receptors expressed onmyeloid cells-2) on humanmono-
cyte-derived DCs leads to marked upregulation of functional
CCR7 despite low expression of costimulatory molecules and
other markers of DC maturation (Bouchon et al., 2001). Mice
deficient in DAP-12, a signaling adaptor for TREM-2, show an ac-
cumulation of DCs in normal skin and gut (Tomasello et al., 2000).
Although TREM-2 ligands remain poorly defined (Klesney-Tait
and Colonna, 2007), it is worthwhile to note that TREM-2 and
DAP12 can regulate some aspects of DC function by interacting
in cis with plexin-A1 and semaphorin D, a receptor-ligand pair
that regulates cytoskeleton and integrin-mediated adhesion
pathways (Takegahara et al., 2006; Wong et al., 2003). Another
member of the plexin family, plexin-C1, has been shown tomedi-
ate the retraction of membrane processes and detachment of
adherent DCs. Consequently, plexin-C1-deficient mice show
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tion to LNs, and retention of LCs in the epidermis (Walzer et al.,
2005).
Detachment
The relatively long persistence and presumably slow turnover of
DCs in some tissues, such as the skin (t1/2 14–30 days), sug-
gests that the tissue microenvironment may provide specific re-
tention signals (Holt et al., 1994; Ruedl et al., 2000). For example,
LCs are anchored in the epidermis through E-cadherin, a homo-
philic adhesion molecule that facilitates intercellular adhesion
and tissue integrity in many organ systems, including the skin,
where it mediates cell-contact junctions with neighboring kerati-
nocytes (Takeichi, 1990; Tanget al., 1993). Selective disruption of
E-cadherin junctions prompts DC migration and maturation,
leading to upregulation of CCR7 without a concomitant increase
in proinflammatory cytokine production (Jiang et al., 2007). TGF-b
might also play a role in retaining LCs because TGF-b1-deficient
mice lack LCs (but not other DC subsets) and their migratory
counterparts in skin-draining LNsdespite thepresenceof LCpre-
cursors (Borkowski et al., 1996). Interestingly, TGF-b upregulates
E-cadherin expression on DC precursors and inhibits their matu-
ration (Geissmann et al., 1999) and CCR7 expression (Sato et al.,
2000). Conversely, IL-1b, TNF-a, and lipopolysaccharide (LPS)
favor DC detachment by decreasing E-cadherin mRNA and
protein expression in DCs (Jakob and Udey, 1998). Therefore, it
appears that DC retention signals are overruled by mobilizing
signals, which bring about detachment from neighboring cells
and matrix components to allow DCs to migrate.
Interstitial Migration
Once a mobilization signal has triggered DC detachment, the
cells must migrate through tissues rich in extracellular matrix
(ECM) proteins, such as collagen types I–IV, fibronectin, and
laminin. Some DCs (e.g., LCs leaving the epidermis) must addi-
tionally traverse a basement membrane before gaining access to
afferent lymphatics. To deal with these obstacles, maturing DCs
upregulate proteolytic enzymes, including membrane-bound
and secreted forms of matrix metalloproteinases (MMPs), partic-
ularly MMP-2 and MMP-9 (Ratzinger et al., 2002; Yen et al.,
2008). Pharmacological inhibition (Lebre et al., 1999) or antibody
neutralization (Kobayashi et al., 1999) ofMMP activity inhibits DC
migration in Matrigel assays as well as LC emigration from skin
explants. Likewise, MMP-9-deficient DCs are markedly defec-
tive in transepithelial migration in vitro (Ichiyasu et al., 2004),
and they also migrate poorly to LNs in vivo (Ratzinger et al.,
2002; Yen et al., 2008). Interstitial DC migration is controlled, in
part, by tissue inhibitors of metalloproteinases (TIMPs), which
function as endogenous regulators of MMP activity and block
DC emigration from skin explants (Ratzinger et al., 2002). DCs
downregulate TIMP expression upon maturation and thus tip
the balance of MMP-TIMP activity in favor of ECM degradation
(Darmanin et al., 2007). Interestingly, the MMP-TIMP system
may exert additional control over leukocyte trafficking via their
action on chemokines. MMP-mediated proteolysis can inacti-
vate chemokines or generate antagonistic or agonistic ‘‘cryptic’’
chemokine derivatives (Van Lint and Libert, 2007), but the
specific consequences of chemokine-MMP interactions for DC
biology are still poorly understood.In addition toacquiring thecapacity to overcomeECMbarriers,
maturing DCs must also develop the means to find local lymph
vessels by switching their chemokine receptor repertoire to one
that favors responsiveness toward LN-tropic chemokines (Dieu
et al., 1998; Sallusto et al., 1998; Sozzani et al., 1998). The
best-validated chemokine pathway for DC migration to LNs is
CCR7 and its ligands, CCL19 and CCL21. Initial studies in mice
homozygous for the paucity of lymph node T cell (plt) muta-
tion—later described as a defect in the production of two of the
threeCCR7 ligands found inmice,CCL19andCCL21-Ser (Luther
et al., 2000; Nakano and Gunn, 2001; Vassileva et al., 1999)—
demonstrated defective DC migration to LNs at steady state
and after contact sensitization (Gunn et al., 1999). These findings
were later substantiated by studies inCcr7/mice (Forster et al.,
1999;Martin-Fontecha et al., 2003;Ohl et al., 2004). Interestingly,
CCR7 ligands are differentially expressed in mice with both
CCL19 and CCL21-Ser localized to the LN paracortex and sub-
capsular sinus (SCS), whereas afferent lymphatics express
both CCL21 isoforms, CCL21-Ser and CCL21-Leu (Vassileva
et al., 1999). Exposure to TNF-a substantially increases CCL21
expression by lymphatic endothelial cells, thus making the reac-
tive vessels evenmore attractive tomigratingDCs (Martin-Fonte-
cha et al., 2003). In plt/plt mutant mice, which express CCL21-
Leu in peripheral lymphatics, but not in LNs, DCs still migrate
out of the epidermis and collect in dermal lymph vessels (Gunn
et al., 1999). Consistent with this, neutralizing antibodies to
CCL21 inhibit the migration of skin-derived DCs into skin-drain-
ing LNs (Saeki et al., 1999), suggesting that the DC migration
defect in plt/plt mice occurred at the level of entry from lymph
into LNs and not into afferent lymphatics, whereas CCR7-defi-
cient DCs are compromised at both steps.
Despite the indispensible role of CCR7 for DC migration to
draining LNs, CCR7 expression is not an obligatory predictor
for this migration event. The capacity to migrate to draining
LNs via lymphatics is much greater for CD8a-/lo DCs than for
CD8ahi DCs (Mempel et al., 2004; Smith and Fazekas de St
Groth, 1999). Mature CD8a+ DCs express uniformly high surface
amounts of CCR7, whereas only 60% of mature CD8a DCs
are CCR7+ (Colvin et al., 2004). This discrepancy is consistent
with a requirement for functional priming of CCR7 activity and
suggests that additional signals, such as lipid mediators (Del
Prete et al., 2007) or other trafficking molecules, may be in-
volved. For instance, epicutaneous sensitization increases
CXCR4 expression on migratory skin DCs, whereas the
CXCR4 ligand, CXCL12, is concomitantly upregulated in dermal
lymphatics (Kabashima et al., 2007). Moreover, CXCR4 inhibition
impairs LC and dermal DC migration to draining LNs after FITC
painting, indicating that both CCR7 and CXCR4 make indepen-
dent contributions. Interestingly, LCs chemotax more efficiently
to CXCL12 than to CCL21; however, when simultaneously ex-
posed to both chemokines they migrate preferentially to CCL21.
Although LCs represent arguably the most prominent DC
population in the skin, a number of other DC subsets, including
dermal DCs, small numbers of pDCs, monocyte-derived DCs,
and the recently described dermal Langerin+ DCs, reside there
(Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007).
The latter subset represents a novel DC population that is
recruited to the skin via the blood in an E-/P-selectin and
CCR2-dependent manner (Ginhoux et al., 2007). These cellsImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 333
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dent fashion to draining LNs, where they present skin-derived
Ags (Bursch et al., 2007; Ginhoux et al., 2007). Not only differen-
tiated DCs but also HSPCs that can give rise to DCs traffic from
the blood through extramedullary tissues into the draining
lymphatics and then recirculate back into the blood via the TD
(Massberg et al., 2007). HSPCs do not express CCR7, but their
egress from tissues into the draining lymphatics is strictly depen-
dent on S1P1 and its sphingolipid ligand, S1P (Massberg et al.,
2007). S1P is abundant in lymph fluid, whereas its interstitial
concentration is very low as a result of rapid degradation by
sphingosine lyase (Cyster, 2005). S1P and its receptors also
play a role in the interstitial migration of fully differentiated DCs,
which express mRNA for all five known S1P receptors and
migrate toward gradients of S1P in vitro (Czeloth et al., 2005;
Maeda et al., 2007). Indeed, small molecule antagonists of S1P
receptors block DC migration to the LNs from the skin (Czeloth
et al., 2005; Gollmann et al., 2008) or lung (Idzko et al., 2006).
Traversing the Afferent Lymphatic Endothelium
DC entry into afferent lymphatics remains poorly understood. It
was initially assumed that entry was an indolent process, al-
though there is now accumulating evidence that a number of
traffic molecules play a role. For example, skin DCs are thought
to enter the afferent lymphatics between overlapping junctions of
oak-leaf-shaped lymphatic endothelial cells in the initial dermal
lymphatics; these cells are connected to each other through sev-
eral molecules, including the junctional adhesion molecules
(JAMs), that form tight and adherens junctions (Baluk et al.,
2007). JAM-A-deficient mice show an increase in DC trafficking
within the afferent lymphatics (Cera et al., 2004), suggesting that
lymphatic endothelium normally restricts DC access.
Human and mouse primary lymphatic endothelial cells upre-
gulate E-selectin, chemokines (CCL5, CCL20, and CXCL5),
and adhesion molecules (ICAM-1 and VCAM-1) after cytokine
stimulation in vitro or in vivo (Johnson et al., 2006). Although
this inducible expression pattern is reminiscent of the molecular
determinants that participate in multistep adhesion cascades in
blood vessels, it is not clear what role selectins or integrins play
in lymph vessels where shear stress is comparatively low. Nev-
ertheless, neutralizing antibodies to ICAM-1 and VCAM-1 block
DC adhesion to and transmigration across lymphatic endothe-
lium in vitro and in vivo (Johnson et al., 2006), and ICAM-1-defi-
cient mice show impaired LC migration to LNs (Xu et al., 2001).
More recently, however, the contribution of integrins was evalu-
ated in DCs that were deficient in all integrin heterodimers
(La¨mmermann et al., 2008). When mutant DCs were injected
subcutaneously, they were able to migrate into the afferent
lymphatics and enter LNs, arguing that at least some DCs can
travel from peripheral tissues into LNs without requiring integ-
rins. Similarly, LC migration into LNs after contact sensitization
is not impaired in FucTVII-deficient mice, which cannot synthe-
size selectin ligands, suggesting that selectins are also not
required (Erdmann et al., 2002).
Although DC traffic into lymphatics is markedly facilitated by
inflammatory signals (Martin-Fontecha et al., 2003), this process
eventually must be turned off to allow restoration of the steady-
state. In this regard, D6, a promiscuous chemokine-scavenging
receptor expressed on lymphatic endothelium, plays an impor-334 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.tant role by controlling the levels of inflammatory chemokines
in tissues (Mantovani et al., 2006). Immune-inflammatory re-
sponses that are self-limiting in wild-type mice go unchecked
in D6-deficient animals, leading to massive inflammatory cell
infiltration due to inadequate clearance of proinflammatory che-
mokines (Martinez de la Torre et al., 2005). It seems likely that
this process also plays a role in the trafficking of DCs into and/
or out of inflamed and healing tissues, but the precise impact
of D6 on local DC dynamics remains to be defined. In addition
to D6, which intercepts inflammatory chemokines, another
nonsignaling chemokine receptor, CCX-CKR1, expressed by
stromal cells in the epidermis and LNs, has been described;
this receptor binds constitutively expressed chemokines (i.e.,
CCL19 and CCL21) and in doing so is thought to regulate the
steady-state migration of CD11c+ MHC-IIhi DCs from the skin
to draining LNs via the afferent lymphatics (Heinzel et al., 2007).
Transit through Afferent Lymphatics
The parameters that control leukocyte movement along the lym-
phatic tree are unclear. The simplest scenario would be that
lymph-borne leukocytes are passively swept into LNs along
the lymph vessels, which drain interstitial fluid in a unidirectional
manner. If so, cellular transit is determined by lymph flow, which
depends on peripheral microvascular permeability; interstitial,
hydrostatic, and oncotic pressure gradients; pulsation of nearby
blood vessels; contraction of skeletal musculature; and the in-
trinsic contractile properties of larger collecting lymph vessels
(Swartz, 2001). Indeed, studies cannulating afferent lymph ves-
sels documented a direct association between changes in lymph
flow and cell yield (Smith et al., 1970). Although biophysical
forces are clearly important for DC transport in lymphatics, it is
unclear whether other factors, such as lymph-borne chemokines
or S1P, could play a modulating role. It is also unknown whether
DCs interact with cellular or structural elements inside lymph
vessels, such as the thread-like structures that have recently
been visualized in collecting lymphatics (Johng et al., 2007), or
whether lymph-borne DCs can actually emigrate from lymph
vessels in regions other than LNs. In support of the latter,
ICAM-1 and VCAM-1 have been shown to be expressed on
both luminal and abluminal sides of the lymphatic endothelium
and support bidirectional DC migration in vitro (Johnson et al.,
2006). Although it is unknown if this occurs in vivo, leukocyte
movement out of lymphatics could bear important conse-
quences for immune surveillance patterns in peripheral tissues.
DC Networks and DC Migration and Motility
within the SLOs
Tissue-derived migratory DCs reach the SCS in draining LNs via
afferent lymphatics, but where and how they enter the underlying
LN parenchyma and what determines their further trajectory
is not completely understood. For example, although several
integrins are highly expressed on DCs, peripheral DCs do not re-
quire these molecules for traveling into and within the LN cortex
(La¨mmermann et al., 2008). Thus, it is unclear how DCs gain
sufficient traction to maneuver through the densely packed LN
parenchyma, which is subdivided into several anatomic com-
partments (Figure 4). Afferent lymphatic vessels, which attach
to the outer surface of the LN capsule and also form continuous
connections with the underlying SCS (Kowala and Schoefl,
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This schematic depicts the DC network and anatomic features within the LN. These include (clockwise from top left) the afferent lymphatics and LN entry point
(inset 1), subcapsular sinus and the peri-follicular region (inset 2), the B cell follicle and T&B cell border (inset 3), the efferent lymphatics and LN exit point (inset 4),
and the T cell zone and HEV (inset 5). Major structural features of the LN are depicted, in addition to T cells (gray circles), B cells (brown circles), and free flowing or
processed Ag (black diamonds). The major trafficking pathways and chemotactic molecules guiding migratory and resident DC subsets within each zone are
highlighted.1986), discharge lymph-borne DCs into the SCS, where they are
retained by unknown mechanisms. To get into the parenchyma,
the newly arrived DCsmust overcome a triple barrier imposed by
the SCS floor. This barrier consists of sinus-lining cells, a layer of
collagenous ECM, and a network of reticular stroma cells that are
sandwiched together and encase the superficial cortex. Evi-
dence suggests that DCs overcome this barrier by following
a gradient of CCL21, which is abundantly expressed in the para-
cortex (Nakano and Gunn, 2001). By contrast, in LNs of plt/plt
mice that lack CCL21, DCs accumulate in the SCS rather than
migrating to the LN paracortex, and consequently, these mutant
mice show increased susceptibility to infection and dysregulated
T cell responses (Gunn et al., 1999; Mori et al., 2001). Further
confirmation came from studies in Ccr7/ mice, which have
fewer and morphologically altered DCs in the paracortex than
wild-type mice (Forster et al., 1999). It has been suggested
that the CCR8-CCL1 axis, in addition to the CCR7 pathway,
might control DC access to the LN parenchyma. CCL1 is ex-
pressed near the outer regions of the SCS and the cortex, and
monocyte-derived CCR8-deficient DCs migrate poorly to LNs,
although they emigrate normally from peripheral tissues (Qu
et al., 2004).CCR7 is also believed to be involved in guiding migrating DCs
deeper into the cortex, where CCL19 and CCL21 are most
strongly expressed in and around HEVs. This may setup an inter-
stitial gradient along which CCR7+ DCs travel. Thus, within one
day after departing from peripheral tissues, lymph-derived ma-
ture DCs become concentrated around HEVs (Bajenoff et al.,
2003). This conspicuous localization may allow newly arrived
DCs to function like a ‘‘welcoming committee’’ by presenting
recently acquired peripheral Ags to both B and T cells that
constantly diapedese across HEVs from the blood (Mempel
et al., 2004; Qi et al., 2006). In addition to following chemokine
gradients, DCs within the T cell area can themselves produce
CCL19 and thus provide a gradient not only for T cells but also
for other mature DCs to reach the T cell zone and perhaps
engage in DC-DC encounters that might lead to the transfer of
antigenic material (Cyster, 1999).
Within themigrating pool, different DCs colonize distinct areas
of the LN. For example, a subset of skin-derived DCs upregu-
lates CXCR5 and becomes responsive to CXCL13, which
attracts them to the follicular region (Saeki et al., 2000) indepen-
dently of CCR7 (Forster et al., 1999). Dermal DCs migrate to the
outer paracortex below B cell follicles, whereas more slowlyImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 335
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senpfennig et al., 2005). The specific cues that confine dermal
DC and LC positioning to these specific areas and the immuno-
logical consequences of this differential distribution remain un-
known. The first migratory DCs require 12–18 hr to reach the
draining LN after Ag challenge in the skin (Kissenpfennig et al.,
2005). By contrast, soluble free Ag can enter the lymph much
more quickly and is processed by LN-resident DCs that initiate
early T cell-priming events within the first 4 hr after Ag challenge.
However, the more slowly moving wave of Ag-bearing skin-de-
rived DCs is required for inducing full-fledged effector responses
(Itano et al., 2003).
Recent MP-IVM studies have provided a glimpse into the
motility and distribution of DCs in LNs. Some have described
the behavior of DCs that had recently arrived through afferent
lymphatics (Bousso andRobey, 2003;Mempel et al., 2004;Miller
et al., 2004b), whereas others have imaged LN-resident DCs
(Hugues et al., 2004; Lindquist et al., 2004). Peripheral migratory
DCs follow random trajectories within the T cell area and exhibit
high motility; they reach a peak 24 hr after their entry into the
LN, and this peak subsides during the following day (Mempel
et al., 2004). By contrast, the LN-resident DCs are organized in
a sprawling network that permeates the perifollicular region
and extends into T cell zone. Most of these resident DCs appear
to be anchored in place, although many display highly motile
dendrites that are thought to enhance the contact frequency
with surrounding T cells (Lindquist et al., 2004).
The extensive dendritic probings and motility exhibited by
LN-resident DCs is dependent on the dynamics of the actin cy-
toskeleton regulated by Rho family GTPases. Inhibition of the
Rac-cdc42-Ral pathway markedly reduces dendritic probings
aswell as short and long-term contacts with T cells in vitro (Swet-
man et al., 2002). Moreover, DCs from Rac1/ or Rac2/mice
show severe alterations in dendrite formation and defective
migration in vivo (Benvenuti et al., 2004). Similarly, interference
in a key downstream effector of the Cdc42 pathway, the Wis-
kott-Aldrich syndrome protein (WASp), leads to defects in DC
trafficking from skin to draining LNs and in DC localization within
LNs (de Noronha et al., 2005). Additional regulation in cytoskel-
etal dynamics is exerted by phosphoinositide 3- kinases
(PI3Ks), which serve as a ‘‘compass’’ by controlling F-actin local-
ization and leukocyte polarity toward chemoattractants (Rickert
et al., 2000). Accordingly, PI3Kg-deficient DCsmigrate poorly to-
ward chemotactic factors in vitro and in vivo, leading to defective
cutaneous hypersensitivity responses in PI3Kg-deficient mice
(Del Prete et al., 2004).
The available MP-IVM observations suggest that newly arriv-
ing migratory DCs initially display much higher motility than their
LN-resident sessile counterparts, but they slow down over time
and eventually join the establishedDC network. The ‘‘motor’’ that
drives DCmotility in LNs has not been identified. However, intra-
nodal T cell motility depends, in part, on CCR7, which interacts
with ligands that are probably immobilized on the branched
FRC network, a collagen-rich organized ECM meshwork that is
ensheathed by fibroblastic reticular cells (Okada and Cyster,
2007; Worbs et al., 2007). This network directs and confines
the seemingly random migration of T cells in the paracortex (Ba-
jenoff et al., 2006) and probably has a role both as a guide for
migratory DCs and as a rigid scaffold for sessile DCs. One could336 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.speculate in this context that the gradual loss of DCmotility after
arrival in the LN might be caused by progressive attenuation of
CCR7 signaling as a result of desensitization or downregulation
of the receptor.
DCs have also been detected in small numbers in TD lymph
(Bell, 1979; Cavanagh et al., 2005), suggesting that not all DCs
that enter LNs stay there. There is evidence that some DCs in ef-
ferent lymph originate from peripheral tissues, but it is not clear
whether and to what extent the LN-resident pool contributes
to this migratory population (Bonasio et al., 2006; Cavanagh
et al., 2005; Dandie et al., 1994). It is also not clear whether tis-
sue-derived migratory DCs trek through the LN parenchyma,
or whether they merely flow through the SCS and/or trabecular
sinuses, to enter efferent lymph vessels. Likewise, whether and
how DCs within the node enter into lymphatic sinusoids to exit
the node has not been determined.
DC Network in Spleen
Multiple signals influence DC positioning and migration within
the spleen. In mice, resting CD8a DCs localize mainly to the
MZ, whereas CD8a+ DCs are enriched in the T cell area (Leenen
et al., 1998). Additionally, some scattered CD11c+ cells can be
found in the red pulp, although the mechanisms that guide
them there are not clear (Metlay et al., 1990). Although DCs
have not been found in the B follicles of resting spleens in
mice, some DCs are detectable in human B cell follicles (Pack
et al., 2008). Because human spleen samples are not ‘‘resting’’
when compared to experimental mice that are typically kept in
a specific pathogen-free environment, it is possible that DCs in
human B follicles represent a subset of activated DCs. This
idea is supported by findings in mice, where a small fraction of
DCs that bind the cysteine-rich domain of the mannose receptor
express CXCR5 upon activation and are attracted to B follicles
by CXCL13 (Yu et al., 2002). However, the vast majority of
splenic DCs enter the T cell zone upon activation because they
upregulate CCR7, which allows them to respond to CCL19 and
CCL21 gradients emanating from the PALS (Reis e Sousa
et al., 1997). There is also evidence that S1P contributes to the
positioning of some splenic DC subsets, although the role of
S1P depends on the immunological context because pharmaco-
logic interruption of the S1P receptor, S1P1, affects the position-
ing of immature but not mature DCs even though mature DCs
express higher levels of S1P1 (Czeloth et al., 2007). Finally, the
intrasplenic distribution of DCs is also influenced by B cell-de-
rived lymphotoxin (LT)-a1b2; DCs must express LTbR to accu-
mulate in the MZ (Wu et al., 1999). However, there is controversy
over whether LTbR is needed for DC positioning within the
spleen or for DC homeostasis (Kabashima et al., 2005).
Concluding Remarks
Here, we have summarized our current understanding of the
mechanisms and consequences of DC migration. The emerging
picture is that of a sophisticated roadmapwhere distinct DC sub-
sets and their precursors follow site-specific and context-de-
pendent traffic signals that have a single purpose: the efficient
dissemination and targeted delivery of biological information
that determines the very nature of both cellular and humoral im-
mune responses. Circulating and recirculating DC precursors
provide a flexible supply of fresh cells to target tissues
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Reviewthroughout the body, where the differentiating DCs acquire an
organ-specific phenotype. Tissue-resident DCs then collect an-
tigenic material while simultaneously gathering intelligence
about the presence and character of innocuous and noxious
events in their surroundings. DCs possess the unique capacity
to integrate and translate the collected information into molecu-
lar recognition patterns for lymphocytes. They then seek out their
cellular audience in lymphoid tissues to provide multi-facetted
instructions that may prevent, promote, or modify immune re-
sponses, as the case may be.
Our roadmap still lacks many of the all-important details. At
every turn along the way we find more questions than answers.
How do DCs and their precursors decide to leave tissues in
the steady state? How do they enter the blood stream? The tho-
racic duct is one established route, but how and where might ex-
travascular cells migrate directly into blood vessels, especially in
the BM, which is thought to be devoid of draining lymph vessels?
What are the specific molecular events that constitute the multi-
step adhesion cascades for DC recruitment from the blood? Are
there tissue-tropic DC subsets, analogous to the organ-specific
effector and memory lymphocytes, in the circulation? What are
the environmental signals that prompt newly homed DC progen-
itors to assume a subset-specific phenotype? Why do some
DCs, especially the CD8a+ subset, fail to gain access to lymph
vessels in peripheral tissues? To what extent do lymph vessels
exert a gate-keeper function for DC migration, and how do
DCs interact with lymphatic endothelial cells? What signals do
DCs perceive while in the lymph? Is their movement through
lymphatics merely a passive ride to the downstream LNs, or
can DCs interact with and perhaps even emigrate from lym-
phatics while en route? What penotypic and migratory changes
do DCs undergo after they have accessed SLOs, and how do
these changes affect their immunogenicity? Why are LNs so
remarkably efficient in retaining migrating DCs but not lympho-
cytes, even though both express CCR7 and S1P1? How do
some rare lymph-borne DCs manage to bypass or depart from
LNs and enter the efferent lymph?Once these escapees have re-
turned to the blood, what is their overall contribution to systemic
immunity and tolerance? One goal, in particular, is especially
coveted: that we as scientists and clinicians can one day exploit
these migratory pathways and drive DCs into the realm of mod-
ern medicine, where many are waiting to go along for the ride.
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